Keywords: Pfizer, Torisel, Ph III, Kidney cancer, Renal cell carcinoma, Combination with Avstin

Pfizer says Torisel combo fails in Ph III for kidney cancer

Article | 13 August 2012

Print This

In a second research disappointment within a matter of days, US drugs behemoth Pfizer (NYSE: PFE) revealed on Friday that ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in